肥胖
灵丹妙药
减肥
背景(考古学)
2型糖尿病
医学
胰高血糖素样肽-1
胰高血糖素样肽1受体
超重
糖尿病
动作(物理)
内分泌学
受体
兴奋剂
生物信息学
内科学
药理学
生物
替代医学
古生物学
物理
病理
量子力学
作者
Georgina K.C. Dowsett,Giles S.H. Yeo
标识
DOI:10.1016/j.molmed.2023.06.008
摘要
Glucagon-like peptide 1 (GLP-1) receptor (GLP-1R) agonists are hugely effective in the treatment of obesity. Originally developed for type 2 diabetes (T2D), these drugs cause dramatic weight loss in people with overweight or obesity, but how do they work, and are these therapeutics the long-sought-after solution to obesity? Here we explain the mechanisms of action of GLP-1R agonists in the context of weight loss and discuss their importance as therapeutics for obesity treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI